PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17664851-2 2007 Both Val-Pro-Pro (VPP) and Ile-Pro-Pro (IPP), which are tripeptides derived from proteolytic hydrolysate of milk casein, inhibit angiotensin-converting enzyme (ACE), suggesting that both VPP and IPP may improve vascular endothelial function, because many ACE inhibitors are known to improve endothelial function. valyl-prolyl-proline 5-16 angiotensin I converting enzyme Homo sapiens 160-163 17664851-2 2007 Both Val-Pro-Pro (VPP) and Ile-Pro-Pro (IPP), which are tripeptides derived from proteolytic hydrolysate of milk casein, inhibit angiotensin-converting enzyme (ACE), suggesting that both VPP and IPP may improve vascular endothelial function, because many ACE inhibitors are known to improve endothelial function. valyl-prolyl-proline 5-16 angiotensin I converting enzyme Homo sapiens 255-258 11999412-3 2002 Val-Pro-Pro, an ACE-inhibitory peptide from fermented milk, was used as a model tripeptide. valyl-prolyl-proline 0-11 angiotensin I converting enzyme Homo sapiens 16-19 34082361-3 2021 Val-Pro-Pro (VPP) is a milk-derived tripeptide with assumed mild inhibitory activity against angiotensin-converting enzyme (ACE). valyl-prolyl-proline 0-11 angiotensin I converting enzyme Homo sapiens 93-122 34082361-3 2021 Val-Pro-Pro (VPP) is a milk-derived tripeptide with assumed mild inhibitory activity against angiotensin-converting enzyme (ACE). valyl-prolyl-proline 0-11 angiotensin I converting enzyme Homo sapiens 124-127 34082361-3 2021 Val-Pro-Pro (VPP) is a milk-derived tripeptide with assumed mild inhibitory activity against angiotensin-converting enzyme (ACE). valyl-prolyl-proline 13-16 angiotensin I converting enzyme Homo sapiens 93-122 34082361-3 2021 Val-Pro-Pro (VPP) is a milk-derived tripeptide with assumed mild inhibitory activity against angiotensin-converting enzyme (ACE). valyl-prolyl-proline 13-16 angiotensin I converting enzyme Homo sapiens 124-127 34082361-4 2021 Computational (DFT) methods are applied on simplified models of Zn2+-HEXXH binding motif without/with bound inhibitors in order to assess the ability of two pharmaceutical drugs (Captopril and Lisinopril) and Val-Pro-Pro to coordinate with Zn2+-HEXXH binding motif of ACE. valyl-prolyl-proline 209-220 angiotensin I converting enzyme Homo sapiens 268-271 19884823-2 2010 Research has mainly focused on isoleucine-proline-proline and valine-proline-proline (IPP + VPP), two lactotripeptides that can inhibit the angiotensin-converting enzyme (ACE) in vitro. valyl-prolyl-proline 62-84 angiotensin I converting enzyme Homo sapiens 140-169 32448573-9 2020 The known ACE inhibitors Val-Pro-Pro and Ile-Pro-Pro showed similar ACE inhibition to previously published results, while also inducing the production of the regulatory cytokine IL-10 by monocytes in the presence and absence of a proinflammatory stimulant. valyl-prolyl-proline 25-36 angiotensin I converting enzyme Homo sapiens 10-13 32448573-9 2020 The known ACE inhibitors Val-Pro-Pro and Ile-Pro-Pro showed similar ACE inhibition to previously published results, while also inducing the production of the regulatory cytokine IL-10 by monocytes in the presence and absence of a proinflammatory stimulant. valyl-prolyl-proline 25-36 angiotensin I converting enzyme Homo sapiens 68-71 33337010-1 2019 Ile-Pro-Pro and Val-Pro-Pro are two most well-known food-derived bioactive peptides, initially identified as inhibitors of angiotensin I-converting enzyme (ACE) from a sample of sour milk. valyl-prolyl-proline 16-27 angiotensin I converting enzyme Homo sapiens 123-154 33337010-1 2019 Ile-Pro-Pro and Val-Pro-Pro are two most well-known food-derived bioactive peptides, initially identified as inhibitors of angiotensin I-converting enzyme (ACE) from a sample of sour milk. valyl-prolyl-proline 16-27 angiotensin I converting enzyme Homo sapiens 156-159 21736845-1 2011 Milk casein-derived angiotensin-converting enzyme (ACE)-inhibitory tripeptides isoleucine-proline-proline (Ile-Pro-Pro) and valine-proline-proline (Val-Pro-Pro) have been shown to have antihypertensive effects in human subjects and to attenuate the development of hypertension in experimental models. valyl-prolyl-proline 124-146 angiotensin I converting enzyme Homo sapiens 20-49 21736845-1 2011 Milk casein-derived angiotensin-converting enzyme (ACE)-inhibitory tripeptides isoleucine-proline-proline (Ile-Pro-Pro) and valine-proline-proline (Val-Pro-Pro) have been shown to have antihypertensive effects in human subjects and to attenuate the development of hypertension in experimental models. valyl-prolyl-proline 124-146 angiotensin I converting enzyme Homo sapiens 51-54 21736845-1 2011 Milk casein-derived angiotensin-converting enzyme (ACE)-inhibitory tripeptides isoleucine-proline-proline (Ile-Pro-Pro) and valine-proline-proline (Val-Pro-Pro) have been shown to have antihypertensive effects in human subjects and to attenuate the development of hypertension in experimental models. valyl-prolyl-proline 148-159 angiotensin I converting enzyme Homo sapiens 20-49 21736845-1 2011 Milk casein-derived angiotensin-converting enzyme (ACE)-inhibitory tripeptides isoleucine-proline-proline (Ile-Pro-Pro) and valine-proline-proline (Val-Pro-Pro) have been shown to have antihypertensive effects in human subjects and to attenuate the development of hypertension in experimental models. valyl-prolyl-proline 148-159 angiotensin I converting enzyme Homo sapiens 51-54 21221598-1 2011 Milk casein-derived tripeptides, valyl prolyl proline (VPP), and isoleucyl prolyl proline (IPP) inhibit angiotensin-converting enzyme (ACE) and both fermented milk and proteolytic hydrolysates of milk casein containing these peptides exert blood pressure-lowering effects in animals and humans. valyl-prolyl-proline 33-53 angiotensin I converting enzyme Homo sapiens 104-133 21221598-1 2011 Milk casein-derived tripeptides, valyl prolyl proline (VPP), and isoleucyl prolyl proline (IPP) inhibit angiotensin-converting enzyme (ACE) and both fermented milk and proteolytic hydrolysates of milk casein containing these peptides exert blood pressure-lowering effects in animals and humans. valyl-prolyl-proline 33-53 angiotensin I converting enzyme Homo sapiens 135-138 21221598-1 2011 Milk casein-derived tripeptides, valyl prolyl proline (VPP), and isoleucyl prolyl proline (IPP) inhibit angiotensin-converting enzyme (ACE) and both fermented milk and proteolytic hydrolysates of milk casein containing these peptides exert blood pressure-lowering effects in animals and humans. valyl-prolyl-proline 55-58 angiotensin I converting enzyme Homo sapiens 104-133 21221598-1 2011 Milk casein-derived tripeptides, valyl prolyl proline (VPP), and isoleucyl prolyl proline (IPP) inhibit angiotensin-converting enzyme (ACE) and both fermented milk and proteolytic hydrolysates of milk casein containing these peptides exert blood pressure-lowering effects in animals and humans. valyl-prolyl-proline 55-58 angiotensin I converting enzyme Homo sapiens 135-138 21779574-6 2011 In particular, Ile-Pro-Pro and Val-Pro-Pro are fore runners in ACE inhibition, and have been incorporated into commercial products. valyl-prolyl-proline 31-42 angiotensin I converting enzyme Homo sapiens 63-66 19884823-2 2010 Research has mainly focused on isoleucine-proline-proline and valine-proline-proline (IPP + VPP), two lactotripeptides that can inhibit the angiotensin-converting enzyme (ACE) in vitro. valyl-prolyl-proline 62-84 angiotensin I converting enzyme Homo sapiens 171-174 20486467-6 2010 It was shown, apparently for the first time, that the inhibitory effects of Ile-Pro-Pro, Val-Pro-Pro and Leu-Pro-Pro on ACE1 at micromolar concentrations are competitive in nature. valyl-prolyl-proline 89-100 angiotensin I converting enzyme Homo sapiens 120-124 20486467-10 2010 The findings support the hypothesis that Ile-Pro-Pro, Val-Pro-Pro and Leu-Pro-Pro act favourably on blood pressure mainly by selective inhibition of ACE1. valyl-prolyl-proline 54-65 angiotensin I converting enzyme Homo sapiens 149-153 19907102-1 2009 AIM: A food-derived bioactive tripeptide, Val-Pro-Pro (VPP), has been shown to possess angiotensin I-converting enzyme (ACE) inhibitory activity and foods containing such peptides exhibit an anti-hypertensive effect in clinical settings. valyl-prolyl-proline 42-53 angiotensin I converting enzyme Homo sapiens 87-118 20721338-1 2010 Tripeptides isoleucyl-prolyl-proline (IPP) and valyl-prolyl-proline (VPP) act as ACE inhibitors in vitro. valyl-prolyl-proline 47-67 angiotensin I converting enzyme Homo sapiens 81-84 20721338-1 2010 Tripeptides isoleucyl-prolyl-proline (IPP) and valyl-prolyl-proline (VPP) act as ACE inhibitors in vitro. valyl-prolyl-proline 69-72 angiotensin I converting enzyme Homo sapiens 81-84 19907102-1 2009 AIM: A food-derived bioactive tripeptide, Val-Pro-Pro (VPP), has been shown to possess angiotensin I-converting enzyme (ACE) inhibitory activity and foods containing such peptides exhibit an anti-hypertensive effect in clinical settings. valyl-prolyl-proline 42-53 angiotensin I converting enzyme Homo sapiens 120-123 19907102-1 2009 AIM: A food-derived bioactive tripeptide, Val-Pro-Pro (VPP), has been shown to possess angiotensin I-converting enzyme (ACE) inhibitory activity and foods containing such peptides exhibit an anti-hypertensive effect in clinical settings. valyl-prolyl-proline 55-58 angiotensin I converting enzyme Homo sapiens 87-118 19907102-1 2009 AIM: A food-derived bioactive tripeptide, Val-Pro-Pro (VPP), has been shown to possess angiotensin I-converting enzyme (ACE) inhibitory activity and foods containing such peptides exhibit an anti-hypertensive effect in clinical settings. valyl-prolyl-proline 55-58 angiotensin I converting enzyme Homo sapiens 120-123 18490081-10 2008 The results of this study demonstrate that the ACE inhibitory peptides Ile-Pro-Pro and Val-Pro-Pro are absorbed partially undegraded. valyl-prolyl-proline 87-98 angiotensin I converting enzyme Homo sapiens 47-50 19619856-5 2009 The levels of ACE inhibitory peptides, Val-Pro-Pro and Ile-Pro-Pro, were increased in the casein miso paste during the fermentation. valyl-prolyl-proline 39-50 angiotensin I converting enzyme Homo sapiens 14-17 19506528-1 2009 BACKGROUND: The potential blood pressure lowering effect of fermented milk may involve inhibition of angiotensin-converting enzyme (ACE) by dairy lactotripeptides generated during milk fermentation, such as isoleucine-proline-proline (IPP) and valine-proline-proline (VPP). valyl-prolyl-proline 244-266 angiotensin I converting enzyme Homo sapiens 101-130 19506528-1 2009 BACKGROUND: The potential blood pressure lowering effect of fermented milk may involve inhibition of angiotensin-converting enzyme (ACE) by dairy lactotripeptides generated during milk fermentation, such as isoleucine-proline-proline (IPP) and valine-proline-proline (VPP). valyl-prolyl-proline 244-266 angiotensin I converting enzyme Homo sapiens 132-135 19506528-1 2009 BACKGROUND: The potential blood pressure lowering effect of fermented milk may involve inhibition of angiotensin-converting enzyme (ACE) by dairy lactotripeptides generated during milk fermentation, such as isoleucine-proline-proline (IPP) and valine-proline-proline (VPP). valyl-prolyl-proline 268-271 angiotensin I converting enzyme Homo sapiens 101-130 19506528-1 2009 BACKGROUND: The potential blood pressure lowering effect of fermented milk may involve inhibition of angiotensin-converting enzyme (ACE) by dairy lactotripeptides generated during milk fermentation, such as isoleucine-proline-proline (IPP) and valine-proline-proline (VPP). valyl-prolyl-proline 268-271 angiotensin I converting enzyme Homo sapiens 132-135 19232015-5 2009 Activities of ACE1 and ACE2 and their inhibition by bioactive tripeptides (Ile-Pro-Pro, Val-Pro-Pro, Leu-Pro-Pro) as well as by a standard ACE-inhibitor captopril were assayed in the vitreous body, the retina and the ciliary body using fluorometric detection methods. valyl-prolyl-proline 88-99 angiotensin I converting enzyme Homo sapiens 14-18 19232015-5 2009 Activities of ACE1 and ACE2 and their inhibition by bioactive tripeptides (Ile-Pro-Pro, Val-Pro-Pro, Leu-Pro-Pro) as well as by a standard ACE-inhibitor captopril were assayed in the vitreous body, the retina and the ciliary body using fluorometric detection methods. valyl-prolyl-proline 88-99 angiotensin I converting enzyme Homo sapiens 14-17 18604316-3 2008 The sequences Val-Pro-Pro (VPP) and Ile-Pro-Pro (IPP), with angiotensin-converting enzyme (ACE) inhibitory activity, have been isolated from these fermented products. valyl-prolyl-proline 14-25 angiotensin I converting enzyme Homo sapiens 60-89 18604316-3 2008 The sequences Val-Pro-Pro (VPP) and Ile-Pro-Pro (IPP), with angiotensin-converting enzyme (ACE) inhibitory activity, have been isolated from these fermented products. valyl-prolyl-proline 14-25 angiotensin I converting enzyme Homo sapiens 91-94 19109662-10 2008 A high proportion of the reported trials was carried out using the well-known ACE inhibiting tripeptides - Valine-Proline-Proline (VPP) and Isoleucine-Proline-Proline (IPP). valyl-prolyl-proline 131-134 angiotensin I converting enzyme Homo sapiens 78-81